Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors

NCT01022853 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: BI 6727
DRUG: BIBF 1120

Sponsor

Boehringer Ingelheim